Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Migraine headaches are theorized to cause aura and symptoms via spreading cortical depression that ultimately results in substance P release, alterations in blood flow, and neurogenic inflammation.
|
31629154 |
2020 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Through activation of NK<sub>1</sub>R, substance P modulates a wide variety of physiological and disease processes including nociception, inflammation, and depression.
|
30538204 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results show a significant upregulation of MAOA and TAC1 in the medial area frontopolaris which is a node in the limbic-cortical network and known to be susceptible for gray matter loss and behavioral dysfunction in patients with depression.
|
29478144 |
2018 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We quantified Tacr1 (neurokinin-1 receptor gene) and Avp (vasopressin peptide gene) mRNA in brain regions involved in depression, addiction and social behavior.
|
28150369 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We consider our findings to contribute to the neurobiological evidence on the association between SP and brain structural changes in depression, which may be related with the pathophysiology and treatment of MDD.
|
28852030 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
More recently, SP and the NK1R have gained attention for their role in complex psychiatric processes including stress, anxiety, and depression.
|
29056150 |
2017 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The study aimed at assessing the concentrations of ADMA, carbonyl groups, CAT and NKA in patients with varying levels of depression severity, PTSD, and depression concurrent with PTSD.
|
28554099 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
In this review, we update the involvement of the SP/NK-1 receptor system in the physiopathology of the above-mentioned pathologies and we suggest valuable future therapeutic interventions involving the use of NK-1 receptor antagonists, particularly in the treatment of emesis, depression, cancer, neural degeneration, inflammatory bowel disease, viral infection and pruritus, in which that system is upregulated.
|
24705689 |
2014 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
The present studies indicate that alterations in substance P/NK1 receptor system underlie, at least in part, the behavioural and monoaminergic changes in this animal model of depression.
|
22155476 |
2012 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression.
|
21912391 |
2012 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Taken together, these data are in line with behavioural experiments showing ameliorating effects of NK1 and NK2 receptor antagonists against anxiety and depression-like symptoms in rodents, and therefore further implicate the tachykinin systems in the pathophysiology of depression and adult life psychopathology.
|
17477887 |
2008 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
However, studies on anxiety and depression-related behaviors have now been performed in mouse mutants deficient in NK1 receptor or SP and NKA.
|
16594257 |
2005 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increasing evidence suggests that substance P (SP) neurokinin-1 (NK1) receptors are involved in stress and emotional responses, representing a potential target for the treatment of anxiety and depression in humans.
|
15845098 |
2005 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because of the possible antidepressant effects of SP antagonists, the influence of SP on both pathophysiology and mitigation of depression has been hypothesized.
|
15157992 |
2004 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, much more research is needed to elucidate the role of SP in the pathogenesis of depression.
|
12692775 |
2003 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review summarizes the pre-clinical evidence derived from pharmacological and transgenic animal studies that suggests an important role for the substance P/neurokinin 1 system in anxiety and depression.
|
12907922 |
2003 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The question is raised whether the present results may be of significance for understanding a possible role of substance P in depression.
|
10716242 |
1999 |